Skip to main content

Clinical trial KEYNOTEC93

A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab versus Platinum Doublet Chemotherapy in Participants With Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma in the First-line Setting (KEYNOTEC93/GOG-3064/ENGOT-en15)

Organ Endometrium
Trial status Trial closed for recruitment
Trial type
Interventional with experimental drug
Phase Trial phase 3
Academic trial Non
Sponsor MSD (Merck Sharp & Dohme)
EudraCT Identifier 2021-003185-12
Last update